Brain

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological Association Annual Meeting CARSON CITY,…

10 months ago

Save the date: IRLAB holds Capital Markets Day on October 17, 2023

GOTHENBURG, SE / ACCESSWIRE / September 11, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 11, 2023 - IRLAB…

10 months ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Conversion Follows $1.0 Million Capital Investment in August 2023KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:…

10 months ago

CENTR Launches Enhanced Gut Health and Cognitive Performance Drinks on Amazon.com

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2023) - CENTR Brands Corp. (CSE: CNTR)  (FSE: 303) (OTCQB: CNTRF) ("CENTR" or…

10 months ago

Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared…

10 months ago

SeatMatch Unveils Industry’s First Neural Network Mapping Recruitment Technology

Innovative recruiting and hiring company leverages new Neural Network Mapping technology of the human brain to increase success rates in…

10 months ago

TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and Its Market-leading Position

TeraRecon partners with different vendors to provide precise, AI-supported patient care and expand in the neurological solutions market and other…

10 months ago

Fortifeye Vitamins Introduces rTG Omgea 3 Fish Oil, a Revolutionary Leap Forward in Nutritional Health

Fortifeye Vitamins - Introducing rTG Omega 3 Fish OilOCALA, FL / ACCESSWIRE / September 7, 2023 / In a groundbreaking…

10 months ago

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase…

10 months ago